Therapeutic Decision-Making in the Adjuvant Setting in HR+ Breast Cancer - Episode 11

The Oncotype DX Breast Recurrence Score for HR+ Breast Cancer

Implications for using the Oncotype DX Breast Recurrence Score to help tailor therapy for patients with HR-positive, HER2-negative breast cancer based on data demonstrated in the TAILORx and RxPONDER studies.